Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
17. Dezember 2020 16:01 ET
|
Vir Biotechnology, Inc.
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17,...